drugset / Trial / NCT04812236

Clinical Study on Wuling Powder in Treating Metabolic Syndrome of Spleen Deficiency and Dampness

NCT04812236 ↗

Phase 4 Unknown 320 enrolled Jiangsu Famous Medical Technology Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

In this study, a randomized, partially double-blind, controlled, multi-center clinical research method was used. A total of 4 groups were designed, namely, single decoction group, co-decoction group, powder group and simulation group. The four groups of patients all received basic health education, diet control and increased exercise guidance. All the patients in the group have taken western medicine according to their own conditions and followed the doctor's instructions for hypoglycemic, blood pressure, and lipid-lowering treatments. After joining the group, they continue to take the medicine at the original dose, and the patients are advised not to change the medicine during the observation period. Take 12 weeks as a course of treatment, and set the observation period to 12 weeks. Follow up every 4 weeks.

Timeline

Start
2021-04-01
Primary completion
2023-02-28
Completion
2023-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Wuling Powder Traditional medicine (herbal / TCM) 5 g —
Subject Wulingsan co-decoction granules Unknown 2 unknown —
Subject Wulingsan single decoction granules Unknown 2 unknown —

Indications